# <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non‐small cell lung cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/i-eml4-alk-i-fusion-variant-v3-is-a-high-risk-feature-conferring-accelerated/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Petros Christopoulos,Volker Endris,Farastuk Bozorgmehr,Mei Elsayed,Martina Kirchner,Jonas Ristau,Ivo Buchhalter,Roland Penzel,Felix Herth,Claus Peter Heußel,Martin Eichhorn,Thomas Muley,Michael Meister,Jürgen R. Fischer,Stefan Rieken,Arne Warth,Helge Bischoff,Peter Schirmacher,Albrecht Stenzinger,Michael Thomas |
| Citations | 138 |
| DOI | 10.1002/ijc.31275 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.31275 |
| OpenAlex ID | https://openalex.org/W2789601608 |
| PMID | 29363116 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Petros Christopoulos](https://scholariq.org/researchers/petros-christopoulos/)

## Paper journal

- [International Journal of Cancer](https://scholariq.org/journals/international-journal-of-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.